Pharvaris (PHVS) Competitors

$17.40

-0.04 (-0.23%)

(As of 07/26/2024 ET)

PHVS vs. AEHAW, ALVOW, ACABW, SUBL, SAVAW, CMRAW, FBIOP, LIXTW, MYNZ, and NLSPW

Should you be buying Pharvaris stock or one of its competitors? The main competitors of Pharvaris include Aesther Healthcare Acquisition (AEHAW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), BioLingus (Cayman) (SUBL), Cassava Sciences (SAVAW), Comera Life Sciences (CMRAW), Fortress Biotech (FBIOP), Lixte Biotechnology (LIXTW), Mainz Biomed (MYNZ), and NLS Pharmaceutics (NLSPW). These companies are all part of the "pharmaceutical products" industry.

Pharvaris vs.

Aesther Healthcare Acquisition (NASDAQ:AEHAW) and Pharvaris (NASDAQ:PHVS) are both manufacturing companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability, community ranking and earnings.

: In the previous week, Pharvaris had 1 more articles in the media than Aesther Healthcare Acquisition. MarketBeat recorded 1 mentions for Pharvaris and 0 mentions for Aesther Healthcare Acquisition. Aesther Healthcare Acquisition's average media sentiment score of 0.63 beat Pharvaris' score of 0.00 indicating that Pharvaris is being referred to more favorably in the news media.
Company Overall Sentiment
Aesther Healthcare Acquisition Neutral
Pharvaris Positive
: Pharvaris has a consensus price target of $32.80, suggesting a potential upside of 88.51%. Given Aesther Healthcare Acquisition's higher possible upside, analysts plainly believe Pharvaris is more favorable than Aesther Healthcare Acquisition.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aesther Healthcare Acquisition
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
Pharvaris
1 Sell rating(s)

0 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.60
: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aesther Healthcare Acquisition N/A N/A N/A N/A N/A
Pharvaris N/A N/A -$109.18M -$2.68 -6.49
: Pharvaris' return on equity of 0.00% beat Aesther Healthcare Acquisition's return on equity.
Company Net Margins Return on Equity Return on Assets
Aesther Healthcare Acquisition N/A N/A N/A
Pharvaris N/A -39.67% -37.38%
: Pharvaris received 34 more outperform votes than Aesther Healthcare Acquisition when rated by MarketBeat users.
Company Underperform Outperform
Aesther Healthcare Acquisition N/A N/A
Pharvaris Outperform Votes
34
65.38%
Underperform Votes
18
34.62%

Company	Overall Sentiment
Aesther Healthcare Acquisition	Neutral
Pharvaris	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aesther Healthcare Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Pharvaris	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aesther Healthcare Acquisition	N/A	N/A	N/A	N/A	N/A
Pharvaris	N/A	N/A	-$109.18M	-$2.68	-6.49

Company	Net Margins	Return on Equity	Return on Assets
Aesther Healthcare Acquisition	N/A	N/A	N/A
Pharvaris	N/A	-39.67%	-37.38%

Company	Underperform	Outperform
Aesther Healthcare Acquisition	N/A	N/A
Pharvaris	Outperform Votes 34 65.38%	Underperform Votes 18 34.62%

Summary

Pharvaris beats Aesther Healthcare Acquisition on 5 of the 7 factors compared between the two stocks.

Ad MarketBeat

We just added a $300 account credit to your MarketBeat subscription

MarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.

Start Your Risk-Free Trial Here

Get Pharvaris News Delivered to You Automatically

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHVS vs. The Competition

Export to Excel

Metric	Pharvaris	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$554.02M	$7.05B	$5.31B	$8.19B
Dividend Yield	N/A	2.82%	2.72%	3.96%
P/E Ratio	-6.49	20.22	152.08	18.37
Price / Sales	N/A	291.03	2,071.74	88.82
Price / Cash	N/A	32.58	35.89	34.13
Price / Book	3.52	5.89	4.95	4.51
Net Income	-$109.18M	$147.89M	$112.29M	$216.36M
7 Day Performance	-5.23%	2.90%	2.73%	1.82%
1 Month Performance	-3.39%	9.07%	6.97%	7.09%
1 Year Performance	3.82%	4.24%	11.22%	4.88%

Pharvaris Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AEHAW Aesther Healthcare Acquisition	0 of 5 stars 0.00 / 5 stars	$0.04 flat	N/A	-76.4%	$0.00	N/A	0.00	2	Gap Up
ALVOW Alvotech	0 of 5 stars 0.00 / 5 stars	$2.68 flat	N/A	+70.4%	$0.00	$112.42M	0.00	4	Gap Up
ACABW Atlantic Coastal Acquisition Corp. II	0 of 5 stars 0.00 / 5 stars	$0.08 flat	N/A	N/A	$0.00	N/A	0.00	4	Positive News
SUBL BioLingus (Cayman)	0 of 5 stars 0.00 / 5 stars	N/A	N/A	N/A	$0.00	N/A	0.00	N/A	High Trading Volume
SAVAW Cassava Sciences	0 of 5 stars 0.00 / 5 stars	$0.03 flat	N/A	N/A	$0.00	N/A	0.00	30	Gap Up
CMRAW Comera Life Sciences	0 of 5 stars 0.00 / 5 stars	$0.00 flat	N/A	N/A	$0.00	$1.00M	0.00	2
FBIOP Fortress Biotech	0 of 5 stars 0.00 / 5 stars	$8.75 -1.0%	N/A	-47.6%	$0.00	$85.11M	0.00	170	Short Interest ↓ News Coverage
LIXTW Lixte Biotechnology	0 of 5 stars 0.00 / 5 stars	$0.07 +15.4%	N/A	-29.4%	$0.00	N/A	0.00	4	Gap Up
MYNZ Mainz Biomed	1.6469 of 5 stars 1.65 / 5 stars	$0.36 +2.9%	$6.00 +1,566.7%	-92.4%	$0.00	$900,000.00	-0.22	30	Short Interest ↑ News Coverage Gap Up
NLSPW NLS Pharmaceutics	0 of 5 stars 0.00 / 5 stars	$0.04 flat	N/A	-55.5%	$0.00	N/A	0.00	6	Short Interest ↑